For research use only. Not for therapeutic Use.
Letosteine is an orally active, potent and safe expectorant. Letosteine dissolves bronchial mucus and reduces respiratory inflammation symptoms, and restores gas exchanges and natural defense mechanisms in the lung. Letosteine can be used for acute or chronic respiratory diseases (such as bronchopneumopathies) research[1][2][3].
Letosteine (Sprague-Dawley rats, 20 mg/kg, IV or Orally, once) is rapidly excreted with mainly in urine[4].
| Catalog Number | I043943 |
| CAS Number | 53943-88-7 |
| Synonyms | 2-[2-(2-ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid |
| Molecular Formula | C10H17NO4S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14) |
| InChIKey | IKOCLISPVJZJEA-UHFFFAOYSA-N |
| SMILES | CCOC(=O)CSCCC1NC(CS1)C(=O)O |
| Reference | [1]. Jia L. Letosteine. John Wiley & Sons, Ltd, 2014. [2]. Macquet V, et al. A new contribution to the treatment of chronic bronchopneumopathies: letosteine. Lille Med. 1979;24(9):735-738. [3]. Zhou Y, et al. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial. Pha [4]. Gachon F, et al. Disposition and metabolism of letosteine in rats. Drug Metab Dispos. 1988;16(6):853-857. |
